Moonlighting functions of ALDOA have also been demonstrated in a recent study by Gizak et al. A slow-binding inhibitor of ALDOA, UM0112176, induces cell death in cancer cells not via the inhibition of the enzymatic activity but through cytoskeletal disruption and caspase activation [8]. Here, ALDOA is linked to cancer.